Neos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHD

DALLAS/FORT WORTH, Texas, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news